Loading...
XNAS
ELAB
Market cap2mUSD
Jul 10, Last price  
1.12USD
1D
0.00%
1Q
-77.87%
IPO
-94.91%
Name

ELEVAI Labs Inc

Chart & Performance

D1W1MN
XNAS:ELAB chart
P/E
P/S
3.68
EPS
Div Yield, %
Shrs. gr., 5y
-28.98%
Rev. gr., 5y
%
Revenues
590k
-76.08%
0827766,2771,712,5952,467,298590,084
Net income
-8m
L+23.41%
-222,910-784,739-1,800,268-4,301,517-6,245,737-7,708,137
CFO
-6m
L+8.14%
-217,164-660,934-1,585,876-4,556,811-5,486,980-5,933,881

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
IPO date
Nov 21, 2023
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT